Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (FWBI) delivers innovative non-systemic therapies targeting gastrointestinal disorders through advanced recombinant protein research. This page consolidates all official announcements, clinical developments, and strategic updates from the biotechnology innovator.
Investors and researchers will find timely updates on FWBI’s MS1819 recombinant lipase program, financial disclosures, and partnership agreements. Our curated feed ensures access to primary-source materials including trial progress reports, regulatory filings, and executive commentary.
The repository features categorized updates spanning clinical trial milestones, peer-reviewed research publications, and strategic corporate developments. Content is rigorously verified to meet financial reporting standards and therapeutic research accuracy.
Bookmark this page for streamlined tracking of FWBI’s advancements in enzyme deficiency treatments and gastrointestinal health innovation. Regular updates ensure you maintain informed perspectives on this clinical-stage biopharma leader.
Entero Therapeutics, formerly First Wave BioPharma, has rebranded to reflect its focus on gastrointestinal (GI) diseases. The company, now trading under the ticker 'ENTO' effective May 17, 2024, is advancing toward a Phase 3 trial for latiglutenase. This lead asset has shown promise in Phase 2 trials for treating celiac disease, a condition with no current approved treatments. The rebranding follows the acquisition of ImmunogenX and aims to align with Entero's mission to address unmet needs in GI health. The Phase 3 trial is expected to commence in early 2025. Entero will also participate in Celiac Awareness Month by partnering with Celiac Journey for a digital display at the Nasdaq Tower in Times Square.
First Wave BioPharma, Inc. is set to raise approximately $1.1 million in gross proceeds through a registered direct offering priced at-the-market. The Company entered into a securities purchase agreement with an institutional investor for the sale of 366,000 shares of common stock at $2.95 per share. Additionally, warrants to purchase up to 732,000 shares will be issued to the investor at $2.70 per share. The offering, facilitated by Roth Capital Partners, aims to bolster the Company's working capital and general corporate purposes.
First Wave BioPharma, Inc. (NASDAQ: FWBI) partners with Celiac Journey for Celiac Disease Awareness Month to host an event at Nasdaq Tower in Times Square. The event aims to raise awareness about celiac disease, advocate for research, and support the 3.3 million individuals in the U.S. impacted by the condition. The company will showcase a digital display and host a photo event featuring celiac disease advocates and experts. CEO James Sapirstein highlights the lack of treatment options for celiac disease and the company's dedication to developing innovative therapies for GI diseases. Co-founder of Celiac Journey, Jax Bari, emphasizes the challenges faced by individuals with celiac disease and the need for improved research funding and alternative treatments. Co-founder Jon Bari stresses the importance of labeling gluten grains for a better quality of life and safety for celiacs.
FAQ
What is the current stock price of First Wave BioPharma (FWBI)?
What is the market cap of First Wave BioPharma (FWBI)?
